Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Centenara Labs

Explore full profile

Creating therapies to improve healthy aging, based on experienced drug discovery

Schlieren, SwitzerlandFounded 2019Biotech & Life Sciences
Valuation $100–500M Latest valuation · 2023
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Centenara Labs and the history behind them.

About Centenara Labs

Rejuveron is a biotech startup that focuses on developing therapies to combat the effects of aging. The company operates in the healthcare market, specifically in the field of drug discovery and development. Its primary clients are individuals seeking to age better and live longer.

Read full description

Rejuveron's business model revolves around creating a pipeline of breakthrough therapeutics that address the hallmarks of aging. These include DNA damage and mutation, senescent cells, telomere shortening, deregulated nutrient sensing, mitochondrial dysfunction, and stem cell exhaustion.

As cells age, their DNA accumulates damage and mutations, and their repair mechanisms start to fail. This promotes aging and disease. Senescent cells, or "zombie cells," are cells that should have died but instead stay alive and negatively affect other cells, causing associated diseases. Rejuveron aims to prevent the accumulation of these cells.

Telomeres, the ends of our chromosomes, get shorter as cells divide, causing cells to age and stop functioning properly. High metabolic activity can stress cells and cause them to age, but when nutrients are limited, cells enter a regenerative mode, which can increase lifespan. Rejuveron is working on mimicking this process to increase health and lifespan in humans.

Mitochondria, the powerhouse of cells, build up oxidative stress and mutations with age, leading to cellular dysfunction and aging. Additionally, stem cells lose their ability to differentiate and replace cells throughout the body as we age, leading to a weak immune system. Rejuveron is developing therapies to address these issues.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
Schlieren, Switzerland
Employees
7
Open positions
None listed
Dealroom signal
63.2/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Biotech and Pharma, EIT Health, Hard Tech, Longevity, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing
Client focus
b2b
Investment activity
3 companies, latest Dec 2021
Capital deployed
$45M
Preferred round
SERIES A

Latest news

Press, funding announcements and product moves mentioning Centenara Labs.

See all news

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SUPPORT PROGRAMOther financing Jan 2024 $1K EIT Health
SERIES BOther financing Sep 2023 $75M $300M Mubadala Capital · Apeiron Investment Group · Catalio Capital Management
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Centenara Labs website traffic

Latest recorded traffic for Centenara Labs is 2.3K monthly website visits, up 820% over the last three months. Centenara Labs's team declined 12.5% over the past year.

Latest monthly visits2.3K 3-month web change+820% 1-year team growth-12.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Apeiron
  • p53 Invest
  • Daniel Gutenberg
  • Apeiron Investment Group
  • Catalio Capital Management
  • Mubadala Capital

Other known investors1 additional known investor

  • EIT Health
Team profiled 11 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇨🇭 Switzerland40%
🇺🇸 United States40%
🇪🇸 Spain20%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Centenara Labs on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Centenara Labs’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.